VAXART INC (VXRT) Stock Price & Overview
NASDAQ:VXRT • US92243A2006
Current stock price
The current stock price of VXRT is 0.32 USD. Today VXRT is down by -25.06%. In the past month the price decreased by -19.09%. In the past year, price decreased by -52.26%.
VXRT Key Statistics
- Market Cap
- 73.03M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.27
- Dividend Yield
- N/A
VXRT Stock Performance
VXRT Stock Chart
VXRT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VXRT. When comparing the yearly performance of all stocks, VXRT is a bad performer in the overall market: 94.13% of all stocks are doing better.
VXRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VXRT. Both the profitability and financial health of VXRT have multiple concerns.
VXRT Earnings
On March 12, 2026 VXRT reported an EPS of 0.24 and a revenue of 104.24M. The company beat EPS expectations (441.01% surprise) and beat revenue expectations (3011.57% surprise).
VXRT Forecast & Estimates
9 analysts have analysed VXRT and the average price target is 3.06 USD. This implies a price increase of 856.25% is expected in the next year compared to the current price of 0.32.
For the next year, analysts expect an EPS growth of 15.8% and a revenue growth -37.03% for VXRT
VXRT Groups
Sector & Classification
VXRT Financial Highlights
Over the last trailing twelve months VXRT reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.66% | ||
| ROE | -127.41% | ||
| Debt/Equity | 0.01 |
VXRT Ownership
VXRT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VXRT
Company Profile
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Company Info
IPO: 1980-03-17
VAXART INC
170 Harbor Way, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Andrei Floroiu
Employees: 105
Phone: 16505503500
VAXART INC / VXRT FAQ
Can you describe the business of VAXART INC?
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 105 full-time employees. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The firm's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Can you provide the latest stock price for VAXART INC?
The current stock price of VXRT is 0.32 USD. The price decreased by -25.06% in the last trading session.
Does VAXART INC pay dividends?
VXRT does not pay a dividend.
What is the ChartMill technical and fundamental rating of VXRT stock?
VXRT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does VAXART INC belong to?
VAXART INC (VXRT) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of VXRT stock?
VAXART INC (VXRT) has a market capitalization of 73.03M USD. This makes VXRT a Micro Cap stock.